This study aims to:
1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.
Clinical diagnosis of Cryptosporidiosis Disease
Age from 5-12 years
Immunocompromised children
Not receiving any drugs causing immunosuppression
Patients undergoing organ transplantation
Patients suffering from autoimmune diseases.
Patients suffering from hypersensitivity of this plant extract